APA (7th ed.) Citation

Loganathan, S., Athalye, S. N., & Joshi, S. R. (2020). Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert opinion on biological therapy, 20(9), 1025-1031. https://doi.org/10.1080/14712598.2020.1798399

Chicago Style (17th ed.) Citation

Loganathan, Subramanian, Sandeep N. Athalye, and Shashank R. Joshi. "Itolizumab, an Anti-CD6 Monoclonal Antibody, as a Potential Treatment for COVID-19 Complications." Expert Opinion on Biological Therapy 20, no. 9 (2020): 1025-1031. https://doi.org/10.1080/14712598.2020.1798399.

MLA (9th ed.) Citation

Loganathan, Subramanian, et al. "Itolizumab, an Anti-CD6 Monoclonal Antibody, as a Potential Treatment for COVID-19 Complications." Expert Opinion on Biological Therapy, vol. 20, no. 9, 2020, pp. 1025-1031, https://doi.org/10.1080/14712598.2020.1798399.